Gluten-free Oats and Gastrointestinal Health in Coeliac Disease, Part 2

Sponsor
University of Turku (Other)
Overall Status
Completed
CT.gov ID
NCT02761785
Collaborator
(none)
49
1
12.1
4.1

Study Details

Study Description

Brief Summary

The research aims to investigate the effects of gluten-free oats to the gastrointestinal health in celiac disease patients and healthy subjects. The effects of gluten-free oats on the several intestinal parameters, on the composition of the gut microbiota as well as on the metabolic profile of celiac patients and healthy controls will be studied. The study is divided into two parts.

Part 1 will be conducted as a double-blind, randomized and placebo-controlled cross-over study. Healthy subjects will be recruited to the study. The aim is to recruit 15 participants for the part 1. The study will be conducted with a cross-over setting, where the subjects will go through exposure meals and SmartPill ingestion three times (two different oat products and placebo) in a randomized order. The study meals are identical in appearance and fiber content. After consuming the meal subjects will ingest the SmartPill capsule, which will send data on intestinal pH, pressure and temperature to the external portable device. Before and during the passage of capsule the subjects will fill a symptom and food diary. The capsule will exit the body in 1 to 3 days and the data collected by the external device will be collected and analyzed. Before the oat/placebo exposure the subjects will give a fecal and a blood sample. In addition, 36 hours urine samples will be collected.

In part 2 celiac disease patients, non-celiac gluten sensitive subjects and healthy controls will be recruited and they will be divided into four groups: oat-avoiding celiacs (1), oat-consuming celiacs (2), non-celiac gluten sensitive subjects (3) and healthy controls (4). Recruiting aim for each group is 15 subjects. In addition to dietary data, a blood, and a fecal sample will be collected from the subjects. The gut microbiota will be analyzed from the fecal samples. The metabolic products will be analyzed from the fecal, urine and blood samples. The gut microbiota composition will be analyzed with next-generation DNA sequencing techniques.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    49 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Cross-Sectional
    Official Title:
    Gluten-free Oats and Gastrointestinal Health in Coeliac Disease, Part 2
    Actual Study Start Date :
    May 29, 2017
    Actual Primary Completion Date :
    May 15, 2018
    Actual Study Completion Date :
    Jun 1, 2018

    Arms and Interventions

    Arm Intervention/Treatment
    Celiacs with oat-related symptoms

    Celiac patients who have self-reported gastrointestinal symptoms after ingestion of gluten-free oats

    Celiacs without oat-related symptoms

    Celiac patients who include gluten-free oats in their diet and have no symptoms related to oats

    Healthy controls

    Healthy controls (without celiac disease) who include oats in their diet

    Non-celiac gluten sensitive subjects

    Subjects with manifestations precipitated by ingestion of gluten in whom celiac disease and wheat allergy are excluded.

    Outcome Measures

    Primary Outcome Measures

    1. Fecal microbiota composition [Measured from single time point sampling]

      Fecal microbiota diversity and composition analyzed from fecal sample

    2. Metabolic status [Measured from single time point sampling]

      Metabolic status analyzed by the amount of metabolic products found in fecal, urine and serum samples

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    15 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Celiac disease diagnosed with duodenal biopsy (only celiac groups)

    • In remission and maintained gluten-free diet >1 year (only celiac groups)

    • Usage of oats in their diet (only oat-using celiacs and healthy controls)

    • BMI 18,5 - 30

    • Normal liver, thyroid and kidney functions

    Exclusion Criteria:
    • Medication that majorly affects GI tract (e.g. laxatives, antacids)

    • Antibiotic treatment within the last 6 months

    • Blood donation or participating in another clinical trial within the last month

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Biochemistry, University of Turku Turku Finland 20014

    Sponsors and Collaborators

    • University of Turku

    Investigators

    • Principal Investigator: Kaisa Linderborg, PhD, Associate professor

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Kaisa Linderborg, Professor of Molecular Food Sciences (acting), University of Turku
    ClinicalTrials.gov Identifier:
    NCT02761785
    Other Study ID Numbers:
    • KAURA2
    First Posted:
    May 4, 2016
    Last Update Posted:
    Oct 11, 2018
    Last Verified:
    Oct 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 11, 2018